PG11144

PG11144 (also known as CGC-11144 or SL-11144) is a synthetic trans-decamine polyamine analogue (oligoamine) originally developed by SLIL Biomedical Corporation and subsequently acquired by Cellgate and Progen Pharmaceuticals. It acts as an epigenetic modulator by inhibiting lysine-specific demethylase 1 (LSD1/KDM1A), which leads to increased global histone H3 lysine 4 (H3K4) methylation and the re-expression of aberrantly silenced tumor suppressor genes. Additionally, due to its high density of protonatable nitrogens, PG11144 exhibits high affinity for DNA, causing DNA aggregation and cell cycle arrest. PG11144 has demonstrated preclinical efficacy in various cancer models, including breast and prostate cancers, as well as in models of choroidal neovascularization (CNV) and parasitic infections.